Key Takeaways
- Binary inflection point approaching: PROSEEK enrollment completed (513 patients), with interim analysis due March-April 2024 and full top-line data in August-September 2024. The outcome will either validate or debunk the cAbl inhibition hypothesis in early Parkinson's, with significant gray space in between.
- Partnership exploration begins now: Management will initiate conversations with potential partners after the interim analysis, aiming to move into Phase-III with a commercialization partner while retaining some development and commercialization role.
- Regulatory path remains undefined: End-of-Phase-II meetings with global agencies will only occur after full data in September; the shape of registrational studies (likely two Phase-III trials) and any possibility of accelerated pathways depend entirely on PROSEEK data and agency discussions.
- Execution risks are explicitly flagged: Management highlighted four major risks: translatability of animal models, lack of a brain target-engagement marker, reproducibility of early proof-of-concept in a larger trial, and the resourcing complexity of Phase-III programs.
- What to watch next quarter: The interim analysis readout and initial partner reactions, any signal on effect size that shapes Phase-III design, and whether the 85-87% rollover rate to the open-label extension carries any interpretable signal.
PROSEEK: The Binary Event
- Trial completed: Enrollment of the target 506 evaluable patients was achieved and concluded around October 2023, ending with 513 patients globally. The program began technically in 2019, with actual dosing starting in early 2020.
- Pandemic impact: The initial years were rough because health systems shut down; hospitals were not seeing patients in-person and many endpoints require practitioners at site. Enrollment was slower than anticipated in the first part but picked up in the last 18 months, helping conclude almost in line with the revised timeline.
- Interim analysis: Planned for late March to early April 2024. The broader organization and external ecosystem (investigators, participants) will remain blinded. Roughly 70 patients are still in different stages of treatment.
- Full data readout: Expected in August-September 2024, after which end-of-Phase-II meetings with the USFDA and other agencies can begin.
- Rollover rate ambiguity: 85-87% of eligible patients continued into the open-label extension Part-II. Management cannot draw definitive conclusions: placebo patients may want to access drug, patients feeling better may want to continue, or patients not feeling better may want to transition from placebo to drug.
Raghavan: "You can have clear validation of this hypothesis. You can also have a clear debunking of this hypothesis, but there's also a lot of gray space in between."
Partnership Strategy
- Timing: Management expects to initiate conversations with potential partners between the interim analysis (March-April) and final data disclosure (August-September). They may not conclude a partnership before full data, but intend to use the time to engage and create interest.
- Interim data sharing: The interim analysis will be shared with a limited number of potential partners under CDA at an appropriate level, to engage early and minimize time required post full data in September.
- Scope and retention: Management is open-minded but the baseline expectation is to retain some level of participation in both development and commercialization. They want to leverage resources and competency of larger partners to fully explore the program in Parkinson's and other indications.
- Strategic intent: Move into late-stage development post-PROSEEK with a partner for commercialization, minimizing the lag between end of Phase-II and initiation of Phase-III.
Raghavan: "We would like to have a relationship which maintain some level of participation in both development and also commercialization of this program, plus some flexibility in terms of additional indications retained within SPARC."
Regulatory Pathway & Phase-III Design
- End-of-Phase-II meetings: Planned with USFDA and other important regulatory agencies, hoped to happen in short order after the August-September data readout. Agencies will require completion of the trial and data from the ITT population before the meeting can occur.
- Registrational package: Traditionally, agencies require two additional Phase-III studies, but other possibilities exist (factoring PROSEEK into the registrational package in some form). The final shape is only clear after discussions with agencies.
- Accelerated approval speculation: Management called the possibility of PROSEEK serving as a registrational study speculative, noting challenges because the Parkinson's field lacks validated biomarkers like Alzheimer's had. It depends on data and regulatory review.
- No interim FDA read: Management has no current plans to share interim analysis data with the FDA. The next planned interaction with the agency on PROSEEK data will be post full data disclosure in September 2024.
- Initial registration setting: Would be a repeat of what was explored in PROSEEK (early treatment-naive setting), the least-risk option from a registration standpoint.
- Phase-III program size: Management cannot comment on the actual size; it depends on statistical considerations, data from PROSEEK on effective doses, the registrational dose to carry forward, and the effect size seen in Phase-II.
- Phase-III preparedness: Management has already started working on some aspects: thinking about the nature of the Phase-III program from a science standpoint, putting together a sense of capability gaps to bridge, and the extent of resourcing required. Full steam can only happen once there is clarity from PROSEEK data.
- Additional requirements: May require additional preclinical studies (particularly toxicity studies like carcinogenicity studies), drug-drug interaction studies, and additional steps for manufacturing, given the size and potential of the drug.
Risks Explicitly Flagged by Management
- Translatability of animal models: No significant clinical translation has been seen in disease-modifying therapies for Parkinson's to date, making the leap from preclinical models to human efficacy a core risk.
- Target engagement uncertainty: There is no target engagement marker in the brain; management approximates by extrapolating animal data, which creates risk around whether the dose is adequate.
- Reproducibility of early studies: Early clinical proof-of-concept studies may not reproduce in a later-stage setting. PROSEEK is powered at approximately 80% to address inadequate powering of early studies, but the risk remains.
- Phase-III execution burden: Extensive additional work is required for Phase-III programs, including resourcing and timely execution across global sites.
- Recruitment momentum assumption: Management expects to maintain the enrollment momentum from the later part of PROSEEK into Phase-III because they now have relationships with investigators and service providers and understand the space better. This assumption is untested.
Beyond Parkinson's: Pipeline Optionality
- Additional synucleinopathies: Lewy body dementia and multiple system atrophy (MSA) are driven by alpha synuclein and require additional preclinical and clinical studies, some of which are underway. SPARC is working with Georgetown on an investigator-initiated trial for lewy body dementia.
- Alzheimer's disease: Early-stage preclinical work is ongoing with academic investigators. If preclinical data continues as expected, Vodobatinib can be explored in Alzheimer's, where cAbl inhibition may have legs in diseases driven by other proteins.
- Backup compounds: There is a backup program for Vodobatinib with additional assets; management may develop an additional backup compound for longer IP life from a composition of matter standpoint for additional indications.
- CML fallback: If PROSEEK is negative, SPARC already has clinical proof-of-concept for CML; it would require an additional study. A decision on investing additional resources or seeking a partner will be taken once there is clarity on the data.
- Symptomatic setting possibility: If PROSEEK shows a trend but not statistical significance, management did not reject the possibility of studying Vodobatinib in a symptomatic setting, but gave a non-committal answer: "We have to take a close look at the data at that point."
Raghavan: "If we go back several years that was the bet that we have taken in that neurodegeneration in spite of conventional wisdom going the other way, we believe that the neurodegeneration is an area is maturing from a science standpoint and that has also been validated recently with several transactions happening in this space."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Interim analysis readout | Blinded data shared internally; limited partner engagement begins under CDA | Late March - early April 2024 |
| Full top-line data disclosure | ITT population data available | August - September 2024 |
| End-of-Phase-II meetings | With USFDA and other global regulatory agencies | Shortly after August-September 2024 data |
| Phase-III initiation | Minimize lag from end of Phase-II; requires agency agreement on registrational studies | Post end-of-Phase-II meetings |
| Partnership execution | Initiate conversations post-interim; aim to conclude with a partner for late-stage development and commercialization | Engagement begins March-April 2024; conclusion may extend beyond September 2024 |
| Long-term extension study | Continue in parallel with Phase-III planning | Ongoing |
| Additional preclinical work | Toxicity studies (e.g., carcinogenicity), drug-drug interaction studies for registrational package | Pre-Phase-III initiation |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| PROSEEK enrollment | 513 patients globally, against a target of 506 evaluable patients |
| Interim analysis patient count | 441 patients, representing 85%-86% of enrolled patients |
| Interim analysis timing | Late March-early April 2024 |
| Full top line data expected | August-September 2024 |
| PROSEEK study power | ~80%, with 500-plus patients |
| Part-I to Part-II rollover rate | 85% to 87% of eligible patients continuing into long-term extension |
| Vodobatinib dosing arms | 384 mg (top dose) and 192 mg (lower dose), 168 patients each, against placebo |
| Part-II extension study duration | 40 weeks (~10 months), with Part-A and Part-B combined for almost 80 weeks |
| Enrollment completion | October 2023, with dosing having started in early 2020 |
| IP coverage for Vodobatinib | Late second half of 2030s |
| Next FDA interaction on PROSEEK | Post full data disclosure in September 2024 |
| Full data set patient count | 513 patients, expected in early September 2024 |